Related Experiment Video
Updated: Jul 14, 2026
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
Published on: March 18, 2014
PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma
Eugene T H Ek1, Crispin R Dass, Karla G Contreras
1Department of Orthopaedics, University of Melbourne, St. Vincent's Hospital, Melbourne, P.O. Box 2900, Fitzroy, 3065, Melbourne, VIC, Australia.
Abstract:
Pigment epithelium-derived factor (PEDF) is one of the most potent inhibitors of angiogenesis, and has recently been demonstrated to have an important multifunctional role in tumor growth, invasion, and metastasis. However, relatively little is known of mechanisms through which PEDF exerts its antitumor activity. Therefore, with the aim of identifying potential functional epitopes specifically against osteosarcoma, we evaluated the bioactivity of four 25-mer synthetic PEDF-derived peptides (termed StVOrth-1, -2 -3, and -4) against a human osteosarcoma cell line, SaOS-2. We found that StVOrth-2 (residues 78-102) predominantly inhibited tumor cell proliferation, while StVOrth-3 (residues 90-114) markedly increased cellular adhesion to collagen type-1, with StVOrth-4 (residues 387-411) demonstrating most significant inhibition of Matrigel invasion. Furthermore, we show that StVOrth-1 (residues 40-64), -2 and -3 induce osteoblastic differentiation, evidenced by increased mineralized nodule formation. Interestingly, although no peptide inhibited angiogenesis in the tube formation assay, StVOrth-3 and -4 markedly suppressed VEGF expression. We further tested the activity of StVOrth-2 and StVOrth-3 in vivo, in an orthotopic model of osteosarcoma and found that both peptides significantly inhibited primary tumor growth and the development of pulmonary metastases. Together these results provide greater insight into the potential mechanisms through which PEDF exerts its antitumor function. Furthermore, this raises the possibility of developing short PEDF fragments as lead compounds for the treatment of osteosarcoma.
Insights
Pigment epithelium-derived factor (PEDF) peptides show promise in treating osteosarcoma by inhibiting tumor growth and metastasis. Specific peptides demonstrated anti-proliferation, enhanced cell adhesion, and induced osteoblastic differentiation, suggesting potential as novel therapeutic agents.
Area of Science:
- Biochemistry
- Oncology
- Molecular Biology
Background:
- Pigment epithelium-derived factor (PEDF) is a potent anti-angiogenesis factor with known roles in tumor progression.
- The precise mechanisms of PEDF's antitumor activity, particularly in osteosarcoma, remain largely unexplored.
- Identifying functional regions within PEDF could lead to targeted osteosarcoma therapies.
Purpose of the Study:
- To identify specific functional epitopes within PEDF for osteosarcoma treatment.
- To evaluate the bioactivity of synthetic PEDF-derived peptides against osteosarcoma cells.
- To investigate the in vitro and in vivo antitumor effects of these peptides.
Main Methods:
- Synthesis and evaluation of four 25-mer PEDF-derived peptides (StVOrth-1, -2, -3, -4) against SaOS-2 human osteosarcoma cells.
- Assays included proliferation, cell adhesion to collagen type-1, Matrigel invasion, and osteoblastic differentiation.
- In vivo studies utilized an orthotopic osteosarcoma model to assess tumor growth and metastasis inhibition.
Main Results:
- StVOrth-2 inhibited tumor cell proliferation; StVOrth-3 enhanced collagen adhesion; StVOrth-4 inhibited Matrigel invasion.
- StVOrth-1, -2, and -3 promoted osteoblastic differentiation and mineralized nodule formation.
- StVOrth-3 and -4 suppressed VEGF expression; StVOrth-2 and -3 significantly inhibited primary tumor growth and pulmonary metastases in vivo.
Conclusions:
- Specific PEDF peptide fragments exhibit distinct antitumor activities against osteosarcoma.
- These peptides demonstrate potential for osteosarcoma treatment by targeting proliferation, invasion, differentiation, and metastasis.
- Short PEDF fragments represent promising lead compounds for developing novel osteosarcoma therapies.
